earnings
confidence high
sentiment positive
materiality 0.75
Regeneron Q3 revenues $3.45B (+51% YoY); GAAP EPS $14.33, non-GAAP $15.37
REGENERON PHARMACEUTICALS, INC.
2021-Q3 EPS reported
$52.29
revenue$11,120,000,000
- Total revenues $3.45B, up 51% YoY; GAAP net income $1.63B ($14.33 diluted EPS); non-GAAP net income $1.77B ($15.37 diluted EPS).
- EYLEA U.S. net sales $1.47B (+12% YoY); Dupixent global net sales (Sanofi) $1.66B (+55% YoY).
- REGEN-COV contributed $804M (U.S. product sales $677M + Roche profit share); new U.S. government supply agreement for 1.4M doses.
- Pipeline: FDA expanded Dupixent to children 6-11 with asthma; positive Phase 3 data in CSU, EoE, prurigo nodularis; REGEN-COV BLA accepted for priority review.
- FY 2021 guidance updated: R&D lowered to $2.845-2.915B GAAP; SG&A narrowed to $1.76-1.83B; gross margin ~87.5% GAAP; capex reduced.